Showing results (31-40 of 92) with videos related to
Sort By:
Pageof 10
Journal of Cancer Research and Clinical Oncology|September 22, 2024
ctDNA responds to neoadjuvant treatment in locally advanced rectal cancerFlorian Bürtin, Liema Elias, Sebastian Hinz, et al.Ophthalmology|May 1, 2014
High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplastyFelix Bock, Mario Matthaei, Thomas Reinhard, et al.Archives of Ophthalmology (Chicago, Ill. : 1960)|April 13, 2011
Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroidsDeniz Hos, Daniel R Saban, Felix Bock, et al.Investigative Ophthalmology & Visual Science|November 18, 2017
Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft SurvivalYanhong Hou, Viet Nhat Hung Le, Thomas Clahsen, et al.Progress in Retinal and Eye Research|January 26, 2013
Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseasesFelix Bock, Kazuichi Maruyama, Birgit Regenfuss, et al.International Journal of Molecular Sciences|June 28, 2023
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer CellsBernd Frerker, Felix Bock, Marie-Louise Cappel, et al.Translational Vision Science & Technology|October 29, 2020
VEGF TrapR1R2 Suspended in the Semifluorinated Alkane F6H8 Inhibits Inflammatory Corneal Hem- and LymphangiogenesisViet Nhat Hung Le, Deniz Hos, Yanhong Hou, et al.Investigative Ophthalmology & Visual Science|April 26, 2008
Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantationDeniz Hos, Felix Bock, Tina Dietrich, et al.Cornea|October 1, 2019
Short- and Long-Term Results of Xenogeneic-Free Cultivated Autologous and Allogeneic Limbal Epithelial Stem Cell TransplantationsJoséphine Behaegel, Nadia Zakaria, Marie-José Tassignon, et al.Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLCJanne Selke, Yvonne Dzierma, Katrin Manda, et al.Pageof 10